Bispecifics: What Moved in 2025 and What Matters Next?
Bispecifics are scaling fast, and 2025 was a year of accelerating pipeline depth, early-stage trial momentum, and more selective (but higher-value) partnering. This review distills the signals that matter most, so you can quickly benchmark the landscape, spot whitespace, and develop your strategy.
Highlights inside:
• Bispecific pipeline expansion and what’s driving it (formats, targets, indications)
• Where clinical activity is clustering globally
• How deal-making changed in 2025: fewer deals, bigger bets
• The IP picture: filing velocity, jurisdictional trends, and where innovation is concentrating
What’s Inside?
The Drug Landscape
An overview of the global bispecific pipeline, covering pipeline growth, development stages, top target pairings, and program discontinuations to show where progress is accelerating and where attrition is setting in.
The Trial Landscape
A snapshot of global bispecific clinical activity, covering trial volume, phase distribution, key trial locations, and top sponsors, showing where clinical momentum is building both geographically and across development stages.
The Commercial Landscape
An overview of bispecific deal-making and company activity, covering deal volume and value, the top 10 deals and developers of the year, where developers are based, and new companies formed in 2025.
Regulatory Announcements
A look at key regulatory activity in 2025, showing the types of update, including IND/CTA approvals, and highlighting the assets with the highest regulatory activity.
The Future of Bispecifics
A forward-looking view of assets to watch and bispecific trials expected to complete in 2026, highlighting programs approaching key clinical inflection points.
Patents Landscape
A clear view of where bispecific innovation is heading, showing who owns the IP, where it’s being filed, how strong it is, and when key patents expire, so you can spot competitive pressure, white space, and long-term risk at a glance.
Previous ADC Landscape Reviews
Bispecific H1 2025 Landscape Review
Bispecific 2024 Landscape Review
Bispecific H1 2024 Landscape Review
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
